Joseph David, MD
Gastroenterology · Phoenix, AZNPI 1700874310
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,775 of the $12,712 with a category attached, or 76.9%. Eli Lilly accounts for 83.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2024 at $8,035 and has fallen 54.7% since, to $3,638 in 2025.
Across 54 payments — averaging $235.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$11K
- Lilly USA, LLC$708
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$289
- E.r. Squibb & Sons, L.L.C.$264
- AbbVie$242
- Johnson & Johnson$152
- plus $444 from 9 others
What the payments were for
- Consulting fees$9,77577%
- Travel & lodging$8397%
- Food & beverage$2,03816%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 6 | $10,614 |
| Lilly USA, LLC | 14 | $708 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $289 |
| E.r. Squibb & Sons, L.L.C. | 3 | $264 |
| AbbVie | 7 | $242 |
| Johnson & Johnson | 3 | $152 |
| Ipsen Biopharmaceuticals, Inc | 1 | $150 |
| Novo Nordisk | 1 | $104 |
| Medtronic | 1 | $56 |
| Bristol Myers Squibb | 1 | $27 |
| Abbott | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Laborie Medical Technologies Corp. | 1 | $22 |
| Celltrion USA Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,712 in reported general payments places this provider in the 80th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 92 | $6,086 |
| MovantikNaloxegol Oxalate | 12 | $4,909 |
| Omeprazole | 259 | $3,135 |
| Ursodiol | 14 | $1,484 |
| Pantoprazole Sodium | 112 | $1,207 |
| Famotidine | 57 | $1,115 |
| CholestyramineCholestyramine (With Sugar) | 13 | $374 |
| Dicyclomine Hcl | 13 | $342 |
| Lansoprazole | 11 | $299 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Phoenix
- Moises Nevah RubinPhoenix$183K
- Alan SheinbaumPhoenix$81K
- Divyesh SejpalPhoenix$45K
- Bradford GelzaydPhoenix$26K
- Rawad MounzerPhoenix$22K
- Aws AlameriPhoenix$20K
- Jonathan MellenPhoenix$17K
- Sarabdeep MannPhoenix$16K
- Layth Al-JashaamiPhoenix$13K
- Joel BrillParadise Valley$847K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.